Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 Profit Margin

Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 (CYCCP) currently reports a profit margin of -214.04% as of March 2026. That compares with 8732.91% in the prior-year period — down 102.5% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's profit margin history and peer comparisons.

Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's profit margin decreased from 8732.91% to -214.04% — a 102.5% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's profit margin of -214.04% is lower than the Healthcare sector average of 15.29%. That is roughly 1499.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's current -214.04% should be judged against Healthcare norms (sector average: 15.29%) and against CYCCP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -214.04%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10, and consider following CYCCP for alerts when major investors trade the stock.